Eisai to Transfer Sales Operations of Inhibace to Chugai

Eisai has agreed with Chugai Pharmaceutical to transfer the sales operations of Inhibace, an antihypertensive agent first synthesized by Roche. Under the terms of the agreement, Chugai will become a sole distributor of Inhibace as of April 1. Inhibace is a long-acting ACE inhibitor for controlling blood pressure. Currently, Chugai is manufacturing the product, and Eisai is solely distributing it in Japan.
Japan Corporate News